NCT07845903Not yet recruiting
A Prospective Study to Observe Clinical Outcomes in Patients Receiving Antiplatelet or Anticoagulant Therapy for Cancer-Associated Acute Ischemic Stroke
A Prospective Observational Cohort Study Evaluating the Effectiveness and Safety of Antiplatelet and Anticoagulant Therapies in Patients With Active Cancer and Acute Ischemic Stroke
Source: ClinicalTrials.gov · Last updated 29 Sept 2026
Brief summary (registry, in English)
The goal of this observational study is to learn about the effectiveness and safety of antiplatelet and anticoagulant treatments in people with a history of cancer who have acute ischemic stroke. The main questions it aims to answer are: * Are there differences in the risk of another stroke between people receiving antiplatelet treatment and those receiving anticoagulant treatment? * Are there differences in the risk of bleeding between the treatment groups? * Which clinical characteristics, imaging findings, cancer-related factors, and blood test results are associated with treatment outcomes? Participants will: * Receive antiplatelet treatment, anticoagulant treatment, or a combination of both, as selected by their treating physicians during routine clinical care. * Provide clinical information and blood samples for the study. * Complete follow-up assessments approximately 30, 90, 180, and 360 days after the stroke. Researchers will compare recurrent stroke, bleeding, other blood clot-related events, functional recovery, and survival among participants receiving different antithrombotic treatments. The study will not assign or change participants' treatments.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 13 Sept 2026
- Start date
- Sept 2026
- Primary completion date
- Aug 2028
- Lead sponsor
- Xuanwu Hospital, Beijing
- Diseases
- Stroke
- NCT number
- NCT07845903
What you commit to
- Study type: Observational
- Planned participants: 60
- From Sept 2026 to the primary completion date, Aug 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Hematologic malignancy.
- Primary intracerebral hemorrhage, subarachnoid hemorrhage, or another non-ischemic type of stroke.
- Transient ischemic attack without evidence of acute ischemic stroke.
- Known severe congenital coagulation disorder.
Other
- Pregnancy or breastfeeding.
- Collection of research blood samples would delay intravenous thrombolysis, mechanical thrombectomy, or other necessary treatment.
- Blood samples that do not meet the prespecified collection requirements or show severe hemolysis.
- Inability to obtain reliable medical history or outcome information from the participant, medical records, or an authorized representative.
Who the study is looking for
- Age 18 years or older.
- Diagnosis of acute ischemic stroke confirmed by clinical evaluation and brain imaging.
- Enrollment within 7 days after symptom onset or the time the participant was last known to be well.
- History of a malignant tumor, regardless of whether the cancer is currently active or inactive.
- Written informed consent provided by the participant or the participant's legally authorized representative.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Xuanwu Hospital, Capital Medical University Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.